ONL Therapeutics is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with retinal disease. They develop innovative therapeutics to prevent the death of key retinal cells and preserve sight.

ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions.

By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need.

ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.

ExSight Ventures

PSQ Capital

Grand Angels

InFocus Capital Partners

Bios Partners

Biosciences Research and Commercialization Center (BRCC)

Capital Community Angel Investors

Johnson & Johnson Innovation – JJDC

Kaitai Capital

MINTS

Alpine Visionary

Visionary Venture Fund

Johnson & Johnson Robotics and Digital Solutions

Mayewell Capital

Michigan Capital Network

We look forward to being a part of the discussion at Eyecelerator @ AAO 2023 this Thursday, and thrilled to have our own David Esposito on the panel "Mapping the Future of Geographic Atrophy." Excited to connect with others that are working to advance eye care innovation!   

https://lnkd.in/gtGPZkGq

Thank you to the Ophthalmology Innovation Summit for the opportunity for ONL’s David Esposito  to be a part of the Platform Innovation panel. We look forward to being part of the discussion!

Thank you to MichBio for hosting the Governor's Roundtable and inviting our COO Connie Chang to be a panelist for this important discussion about the life sciences industry Michigan.

The ONL team applauds the countless accomplishments and contributions to the biotech community of our board member Dr. Stella Robertson. With her influence extending far beyond the boundaries of her home state, she has made positive impacts across many domains including scientific research, biotech innovation, and women in business, to name just a few. Bravo!

ONL Therapeutics stands with the International Agency for the Prevention of Blindness (IAPB) to put a spotlight on today's World Sight Day to promote eye health habits that will benefit the well-being, safety and productivity of millions of people around the world.

Daniel Levine of The Bio Report recently spoke with Connie Chang, ONL COO, to talk about ONL's clinical program investigating ONL1204 for multiple blinding diseases of the eye. Thanks for sharing ONL's story.

We are continuing to share the unique mechanism of action unpinning our lead compound with an Empowered Patient Podcast featuring David Esposito, CEO. Thanks, Karen Jagoda, for hosting a terrific discussion.

We are pleased to announce an important milestone for ONL: the completion of enrollment for our Phase 2 study of ONL1204 Ophthalmic Solution in patients suffering from rhegmatogenous retinal detachment. Thank you to all the patients, investigators and sites for their collaboration!

Check out a recent article featuring ONL's CEO David Esposito in Applied Clinical Trials Magazine: Preserving Sight: A Deep Dive into ONL Therapeutics' Innovative Approach to Combat Retinal Disease.

On this Clinical Trials Day 2023 we are hosting an investigator meeting for our Phase 2 clinical trial studying ONL1204 Ophthalmic Solution in retinal detachment patients. Thank you to all the clinicians, research staff and patients participating in this clinical study as well as our ongoing trials in geographic atrophy/AMD and open-angle glaucoma. #clinicaltrials #research #thankyou

COM:ONLTHERAPEUTICS

ONL Therapeutics

Financials Not Available